What Cardiff Oncology, Inc. does.

We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care ("SoC") therapeutics. We are focusing our clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), metastatic triple negative breast cancer ("mTNBC") and Chronic Myelomonocytic Leukemia ("CMML"). Our clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.

Onvansertib is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life.

We believe the attributes of onvansertib described below, as well as early clinical evidence of favorable safety and efficacy, with expected on-target, manageable and tolerable side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers:

Revenue and profit, by fiscal year.

More on CRDF.

• Cardiff Oncology, Inc. summary
• Cardiff Oncology, Inc. financial statements
• Cardiff Oncology, Inc. key metrics
• Cardiff Oncology, Inc. health scores and style box
• Cardiff Oncology, Inc. earnings
• Cardiff Oncology, Inc. dividends
• Cardiff Oncology, Inc. valuation
• Cardiff Oncology, Inc. ownership and insiders
• Cardiff Oncology, Inc. peers

Figures from Cardiff Oncology, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.